Alzheimer’s Disease

Disclaimer:
This blog is for informational purposes only and should not be taken as medical advice. Content is sourced from third parties, and we do not guarantee accuracy or accept any liability for its use. Always consult a qualified healthcare professional for medical guidance.

What is Alzheimer’s?

Alzheimer’s Disease is a progressive, irreversible neurodegenerative disorder characterized by the accumulation of amyloid-beta plaques and tau protein tangles in the brain, leading to neuron loss, synaptic dysfunction, and cortical atrophy, primarily affecting memory, thinking, and behavior. It begins with mild cognitive impairment (MCI) in the entorhinal cortex and hippocampus, progressing to severe dementia with global cognitive decline, loss of independence, and complications like infections or falls. In 2025, it affects 6.9 million Americans over 65, with risk factors including age (doubles every 5 years after 65), genetics (APOE e4 allele triples risk, rare familial mutations in APP, PSEN1/2 cause early-onset), cardiovascular disease, head trauma, and low education. Stages include preclinical (biomarker-positive but asymptomatic), mild (memory lapses), moderate (confusion, mood changes), and severe (total dependence), with average duration 8-10 years from diagnosis.

How MRI is Used for It

MRI is integral for Alzheimer’s, showing structural changes like hippocampal atrophy (volume reduction >20% in early stages), cortical thinning in temporal/parietal lobes, and ventricular enlargement, with volumetric analysis (e.g., FreeSurfer software) quantifying changes for diagnosis and progression tracking with 85% accuracy when combined with AI. It rules out mimics like vascular dementia or tumors, while functional MRI (fMRI) assesses connectivity disruptions in default mode networks, and perfusion MRI detects hypoperfusion in affected regions. In 2025, AI-analyzed MRI predicts conversion from MCI to Alzheimer’s with 90% accuracy, and amyloid-sensitive sequences (with contrast) visualize plaque burden, aiding early intervention.

What the Future Outlook is

In 2025, Alzheimer’s has no cure, but disease-modifying therapies like lecanemab (anti-amyloid antibody) slow progression by 27% in early stages, with 5-year survival post-diagnosis at 40%, mainly due to comorbidities. Future research emphasizes anti-tau therapies, gene editing to reduce APOE e4 risk, and stem cell transplants for neuronal replacement (phase I trials showing safety). AI predicts onset 5-7 years early from MRI data, enabling preventive lifestyle interventions. By 2030, combination therapies could delay onset by 5 years in high-risk groups, reducing prevalence by 20%, with focus on vascular health and personalized medicine.

What Diagnosis is Used

Diagnosis of Alzheimer’s involves clinical criteria (NIA-AA), cognitive testing (MoCA, MMSE for memory/attention deficits), and biomarkers. MRI assesses atrophy, while PET scans detect amyloid/tau. CSF analysis measures amyloid-beta and tau levels. Blood tests for p-tau217 (90% accuracy in 2025) enable early screening. Genetic testing identifies APOE status or rare mutations. In 2025, AI integrates multimodal data for 95% diagnostic precision, reducing misdiagnosis from vascular or Lewy body dementia.

Sources

The information is sourced from the Alzheimer’s Association’s “MRI in Alzheimer’s Diagnosis,” 2025 for how MRI is used; National Institute on Aging’s “Alzheimer’s Disease Fact Sheet,” 2025 for condition overview; PMC’s “Imaging Biomarkers in Alzheimer’s Disease,” 2025 for future outlook.